APHID - Action plan for hit identification 


Due to initiatives such as the National Drug Discovery Centre (WEHI), high-throughput screening (HTS)

approach has become more accessible for drug discovery researchers. However a lack of downstream

medicinal chemistry expertise makes data analysis and data mining challenging tasks.

To bridge the gap, a hit triage expert group (APHID) is formed and located within Australian Translational Medicinal Chemistry Facility (ATMCF), one of TIA’s Small Molecules facilities. The APHID capability aims to provide Australian researchers from academia and/or SMEs confidential advice, feedback and guidance on further development of their identified hits following HTS screening campaigns. 


For conventionally sized sets of HTS, APHID utilises e-SAR (electronic structure-activity relationship) to follow-up on the initial target hits by performing relevant SAR studies and assess the feasibility of sourcing the follow-up sets of molecules/compounds of interest.

Criteria for application selection

There is no priority target disease. Not all applications will be able to receive advice and feedback. The project will be assessed according to factors such as:

  • scientific quality of the project and reliability of assay

  • composition of the library screened

  • biological validity of the target

Access to APHID is at no cost for TIA Pipeline Accelerator voucher recipients. Outside of this scheme, please contact ATMCF via the contact below.

APHID reporting

Successful applicants will receive a report generally around 3-4 weeks following submission. The report will outline the compounds and SAR sets which have been identified as tractable against their specific targets. Further guidance as to the best next steps on the applicants’ drug development journey may also be provided.


Dr Leanne Hawkey,

ATMCF Facility Manager

T: +61 3 9903 9563 

E: atmcf@monash.edu

E: leanne.hawkey@monash.edu

W: monash.edu/atmcf

ATMCF_new logo.png